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INTRODUCTION:  The  risk  of  periampullary  neoplasia  in  patients  with  familial  adenomatous  polyposis
(FAP)  is signiﬁcantly  increased  compared  to  the  general  population.
PRESENTATION OF  CASE:  We  herein  report  the  case  of a  47-year-old  woman  with  classic  familial  ade-
nomatous  polyposis  with  a history  of  total  proctocolectomy  for FAP  who  presented  with  an  ulcerous
ampullary  lesion  8 years  after  primary  colorectal  surgery.  Interestingly,  the  patient  had not  enrolled
to  optimal  postoperative  upper  endoscopy  follow-up.  The  patient  underwent  a Whipple  procedure.
Histology  demonstrated  a T2N0  ampullary  adenocarcinoma.
DISCUSSION: Periampullary  disease  in  patients  with  familial  adenomatous  polyposis  occurs  increasingly,otal  proctocolectomy
ndoscopy
especially  in  the  subset  of patients  without  proper  endoscopic  follow-up.  Current  recommendations  con-
cerning  upper  endoscopy  and  appropriate  management  are  herein  discussed;  the  importance  of  optimal
postoperative  endoscopy  after  total  proctocolectomy  in  the FAP  setting  is discussed.
CONCLUSION: Periampullary  cancer  carries  a signiﬁcant  risk  in patients  with  FAP  and  proper  endoscopic
follow-up  should  be applied  in this  special  patient  group  in  order  to  manage  ampullary  manifestations
of  the  disease  in  a timely  manner.
gical  © 2013 Sur
. Introduction
Familial adenomatous polyposis carries a nearly 100% prob-
bility of colorectal cancer in untreated subjects. Interestingly,
mpullary disease secondary to FAP can progress to truly invasive
denocarcinoma, therefore representing a condition with signiﬁ-
ant morbidity in affected patients. We  herein describe the case
f a female patient previously undergone a total proctocolectomy
or FAP. The patient did not enroll to an optimal postopera-
ive endoscopy protocol and subsequently represented with a
etachronous development of an invasive ampullary adenocarci-
oma 8 years after primary colorectal surgery.
. Presentation of case
A 47-year-old Caucasian female was admitted to our Surgi-
al Department complaining of epigastric pain and vomiting. She
ad a history of classical FAP for which she had undergone a
otal proctocolectomy 8 years ago. Pathology report at the time
as negative for colorectal cancer. Due to reported socioeco-
omic and major personal issues the patient did not conform to
roper postoperative endoscopic follow-up. Past medical history
lso included hormonal replacement for hypothyroidism. Upon
∗ Corresponding author at: 2nd Department of Propedeutic Surgery, “Laiko” Gen-
ral Hospital, Ag. Thoma 17, 11527 Goudi, Athens, Greece. Tel.: +30 2107456972;
ax:  +30 2107456972.
E-mail address: pcharalampoudis.laiko@gmail.com (P. Charalampoudis).
210-2612 ©  2013 Surgical Associates Ltd. Published by Elsevier Ltd. 
ttp://dx.doi.org/10.1016/j.ijscr.2013.05.006
Open access under CC B Associates Ltd. Published by Elsevier Ltd. 
admission, abdominal ultrasound revealed a distended distal com-
mon  bile duct. Complete blood count was unremarkable. Serum
biochemistry demonstrated LFTs disturbance (ALP 718 mg/dl, -GT
283 mg/dl, SGOT 284 mg/dl) while total bilirubin and serum tumor
markers (CEA, CA 19.9) were within normal range.
Further investigation with ERCP and subsequent MRCP demon-
strated an ulcerous, round-shaped lesion located in the ampulla of
Vater causing distention of the distal CBD. Lesion biopsy suggested
ampullary adenocarcinoma. The patient underwent a Whipple pan-
creatoduodenectomy with an uneventful postoperative course. She
was discharged on the 9th postoperative day. Final pathology
report was  conclusive for a T2N0 ampullary adenocarcinoma.
Upper endoscopy at 1 year after the operation was negative for
local recurrence. Abdominal computed tomography was  similarly
negative for metastatic disease. The patient remains asymptomatic
and in a good general condition 1 year after the operation.
3.  Discussion
Familial adenomatous polyposis (FAP) is an autosomal domi-
nant inherited polyposis syndrome caused by a germline mutation
in the adenomatous polyposis coli (APC) gene on chromosome
5q21.1 The disease is characterized by the early onset of hundreds
to thousands of adenomas throughout the colon; nearly 100% of
patients will progress to developing colorectal cancer by the age
Open access under CC BY-NC-ND license.of 35–45 years old if left untreated.1–3 Early prophylactic colorec-
tal surgery has changed the prognosis of patients with FAP, and
nowadays desmoid tumors and periampullary duodenal cancers
are the most common causes of death in these patients, rather than
Y-NC-ND license. 
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olorectal cancer per se.1,3,4 For polyps located in the ampulla of
ater and the periampullary area, the estimated frequency of devel-
ping cancer via the adenoma–carcinoma sequence is between
% and 12%.3 The risk of carcinoma is greater in ampullary com-
ared with nonampullary adenomas and increases with the size of
denoma3,4; it is therefore very important to scan and biopsy the
apilla, even when it is macroscopically normal.3
Several studies have tried to identify a genotype–phenotype
elation  between speciﬁc mutation sites of the APC gene and the
everity of duodenal and periampullary adenomatosis, but the
esults have been inconsistent. Five studies indicated correlations
ith mutations in codon 157–416, codon 279–1309, exon 15 after
odon 1400 and exon 10, respectively, whereas two studies found
o correlation between mutation sites and the severity of ade-
omatosis or carcinoma development.5 In our case, we did not
anage to perform any genetic mutation analysis, as genetic coun-
eling in Greece is not covered by routine social security programs;
onsequently our patient did not conform to affording for such an
nalysis herself.
In  1989, Spigelman et al. published an endoscopic and histolog-
cal classiﬁcation system for evaluation of the severity of duodenal
denomatosis; the Spigelman classiﬁcation has become the gold
tandard in several studies of duodenal adenomatosis.6 Patients
ith advanced Spigelman stages are most at risk of developing
uodenal carcinoma1; the risk of developing duodenal cancer is
reatest for patients with stage IV disease, with rates of 7–36%
escribed over follow-up periods of 7.6–10 years.3,4 Conversely,
he risk of developing duodenal cancer in stage 0-III disease over a
imilar period is as low as 0.7%.4 Progression to higher stages occurs
ver time with one study showing 15% of patients progressing from
tages 0-III to stage IV disease over a period of 8 years.4
The frequency of endoscopic examinations is determined by the
pigelman stage, with a shorter duration between examinations
or more advanced stages, the aim being to detect stage IV disease
efore duodenal or ampullary cancer has developed. There is a fair
egree of agreement in published recommendations regarding the
requency of endoscopic surveillance in patients of a speciﬁc Spigel-
an  stage; slight differences concern mainly the use of imaging,
hemoprophylaxis and endoscopic intervention.4
.1. Spigelman stage speciﬁc recommendations
Stage  0-I disease: recommendations agree to 5 yearly
endoscopy.5,7,8
Stage II disease: recommendations agree to 3 yearly endoscopy;
Groves  et al. suggest the potential use of additional endoscopic
therapy via endoscopic mucosal resection (EMR).5,7,8
Stage III disease: recommendations agree to 1 to 2 yearly
endoscopy; Gallagher and Groves both suggest adjuvant celecoxib
therapy  and endoscopic therapy for stage III lesions.5,7,8 A random-
ized  controlled trial showed that celecoxib 800 mg  daily resulted
in  a reduction in duodenal adenomatosis. However, there are yet
no long term results concerning adenomatosis development or a
cancer protective effect induced by cox-2 inhibitory agents.3,5,7
Stage IV disease: recommendations generally agree to the use
of  EUS/CT for proper lesion staging and subsequent surgery.5,7,8
Endoscopic ultrasonography (EUS) has been reported to have a
sensitivity of between 80% and 97% in identifying malignancy in
sporadic ampullary lesions smaller than 2 cm.  It provides an accu-
rate method of evaluating the stage of ampullary malignancies,
particularly the depth of inﬁltration into the pancreas.7 Bulow
et  al. provided evidence that a surveillance program based on
the  Spigelman classiﬁcation combined with cancer prophylactic
surgery  in selected patients results in a considerable improvementPEN  ACCESS
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of the prognosis after duodenal cancer, caused by early detection
at  a presymptomatic stage.9
3.2. FAP-related periampullary disease
As previously mentioned in Section 3, the risk of carcinoma is
greater in ampullary adenomas compared with nonampullary ones
and increases with the size of adenoma.3,4 Latchford et al. have
observed that all ampullary cancers arose in polyps greater than
1 cm.  This is also supported by the ﬁndings of Kashiwagi et al. who
noted that major ampullary polyposis (deﬁned as an ampullary
polyp > 1 cm, exhibiting moderate/severe dysplasia or a villous
architectural component) was  more likely to progress to malig-
nancy than ampullary adenomas less than 1 cm with mild dysplasia
and no villous component (deﬁned as minor polyposis). Latchford
et al. therefore proposed a different endoscopic surveillance proto-
col for patients with disease located in the periampullary region;
for major polyposis of the ampulla, patients should undergo annual
surveillance, irrespective of Spigelman staging of the nonampullary
disease. If there is evidence of disease progression then endoscopic
ultrasound and magnetic resonance imaging of the pancreaticobil-
iary tract should be performed to assess the ampulla further with a
view to endoscopic or surgical resection, depending on local exper-
tise. Minor polyposis of the ampulla should be monitored every 3
years. If there is disease progression, further assessment should
be performed as outlined earlier. If the ampulla is entirely normal
macroscopically (many patients will have adenomatous change
pathologically even if macroscopically normal), then surveillance
should be performed every 5 years or as deﬁned by the Spigelman
staging of the nonampullary duodenal disease.10
3.3. Management
Optimal treatment of periampullary adenomatosis-as for non-
ampullary duodenal adenomatous lesions should include complete
and lasting destruction of adenomas with a minimum risk of com-
plications and no functional problems. Such a treatment is not
yet available but several options have been tried, mainly includ-
ing endoscopic approaches, local ablation techniques and radical
surgery.5
Endoscopic ampullectomy is the technique of choice for some
growths that appear in the ampulla of Vater. The criteria determin-
ing whether or not they are removable using this technique vary
from study to study, although most studies state that polyps with
severe displasia and stages Tis and T1 can be resected if there is no
lymphovascular invasion, and if the growth is completely resected.
This type of treatment is discarded if there is intraductal invasion,
except where the adenomas have mild dysplasia and intraductal
growth of less than 1 cm.  Morbidity associated with this technique
is 23% (with a range of 10–58%), and mortality is 0.4% (ranging from
0% to 7%). The principal complications are pancreatitis (8–15%), per-
foration (0–4%), bleeding (2–13%), cholangitis (0–2%) and papillary
stenosis (0–8%).3
Transduodenal excision had been previously advocated as the
ﬁrst procedure of choice, but the high recurrence level, up to 100%
in some groups, has led to its disuse.3 Surgical ampullectomy is
one alternative for those patients with ampullary polyps for whom
endoscopic treatment is not safe. In a published study of eight
patients, mortality and morbidity were relatively low (1 of 8),
with no relapses observed in a 58-month surveillance period. The
primary postoperative complication was a duodenal ﬁstula, and
during surveillance one patient suffered acute pancreatitis because
of stenosis of the pancreatic anastomosis.3
Radical surgery has included cephalic pancreatico-
duodenectomy (Whipple’s operation).2,5 Its risk of complications is
acceptable, although in some groups a perioperative mortality rate
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f 2–9% has been observed and postoperative complications rates
an be as high as 41%. The Whipple procedure should be used for
ore advanced growths-larger than 2 cm or invasive carcinomas.3
aillie et al. showed that pylorous preserving pancreatoduo-
enectomy (PPPD) is a safe and feasible procedure in patients
ith Spigelman IV lesions or invasive periampullary cancer.
,3
. Conclusion
Foregut cancer in patients with FAP represents a serious con-
ition with signiﬁcant morbidity. Although total proctocolectomy
as changed the perspective for these patients pertaining to
olorectal cancer, upper gut and especially periampullary adeno-
atosis can progress to truly invasive adenocarcinoma through the
denoma–carcinoma sequence. The mainstay of management in
his setting is the enrollment in a lifetime upper endoscopy protocol
ith the intent to diagnose and treat any foregut polypoid lesions in
 timely manner and offers a chance for cure when invasive cancer
ccurs.
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